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Graphical abstract 
 
 
DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor 
activity in vincristine-resistant oral epidermoid carcinoma  in vitro and in vivo 
Abstract 
  Multidrug resistance (MDR) is one of major obstacles to effective chemotherapeutic 
treatment of cancer. This study showed that DHPAC, 2-(6-ethoxy-3-(3-ethoxyphenylamino) 
-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy) acetamide, a novel compound that binds 
to the same site on microtubules as colchicine, has high anti-tumour activity in 
vincristine-resistant oral epidermoid carcinoma (KB/V) cells. It found that the presence of 
DHPAC strongly inhibited KB/V cell growth in vivo and in mice xenograft. The inhibitory 
effect of DHPAC is much stronger than that by colchicine in these KB/V cells (IC50: 64.4 nM 
and 458.0nM respectively). Treatment of the cells with DHPAC induced cell apoptosis by 
reducing mitochondrial membrane potential and altered the expression of several 
apoptosis-related proteins such as Bcl-2, Bax, Caspase-9, Cytochrome c and PARP. DHPAC 
treatment also caused cell rest in G2/M phase by regulating of the expression of a number of 
cell cycle-related proteins (e.g. Cyclin B1, Cdc2, Cdc25b, Cdc25c, RSK2). Furthermore, 
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DHPAC presence inhibits PTEN phosphorylation and PTEN/Akt/NF-κB signalling. Thus, 
DHPAC has potent anti-cancer activity in MDR tumuors and may be a potential therapeutic 
agent for the treatment of vincristine-resistant human oral epidermoid carcinoma.  
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1. Introduction 
Multidrug resistance (MDR), in which tumor cells develop cross-resistance to classes of 
functionally and structurally unrelated antitumor drugs (Abdallah et al., 2015), is one of the 
most common problems in the treatment of malignant tumors. Overexpression of drug efflux 
proteins such as P-glycoprotein (P-gp), alteration of topoisomerase II activities, and mutation 
of P53 by tumor cells are all believed to contribute to MDR in cancer treatment (Luqmani, 
2005). P-gp (ABCB1) is a 170-kDa transmembrane protein and a member of ATP-binding 
cassette (ABC) transporters. It is intrinsically over-expressed in many types of tumors such as 
colon, rectum, liver, and kidneys (Patel and Rothenberg, 1994). Research approaches try to 
overcome P-gp-associated drug resistance include that the use of anti-cancer drugs with novel 
P-gp inhibitors (Binkhathlan and Lavasanifar, 2013).  
  Microtubules are key components of the cytoskeleton with polymerizing α-tubulin and 
 4 
β-tubulin heterodimers. They play important roles in maintaining cell shape, proliferation, 
division, signaling, and trafficking in eukaryotic cells (Perez, 2009; Jordan and Wilson, 2004). 
Because of its ability of forming mitotic spindle that affects segregation of the replicated 
chromosome during cell division, microtubules are excellent drug targets for tumor therapy 
(Parker et al., 2014). Some tubulin binding agents (e.g. vinca alkaloids, colchicine) have 
shown to inhibit microtubule polymerization and some others (such as taxanes), have shown 
to inhibit microtubule depolymerization (Yan et al., 2015).  
  The microtubule binding agent colchicine was approved by FDA in 2009 as a 
mono-therapy drug to treat familial mediterranean fever and acute gout flares (Lu et al., 2012), 
but is no longer used as a chemotherapeutic drug in clinic due to its high cytotoxicity. Diverse 
efforts have been made over the past years to develop new agents that can target the same 
colchicine binding site on microtubules to prevent neovascularization and multidrug 
resistance (MDR) (Lu et al., 2012). DHPAC, 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1- 
methyl-1,4-dihydroindeno[1,2-c] pyrazol-7-yloxy) acetamide, is a novel synthetic compound 
that has high binding affinity toward the same colchicine binding site on microtubules and 
exhibits potent anti-tumor activity on non-small cell lung cancer (NSCLC) (Liu et al., 2016). 
This study investigated the anti-tumor effect of DHPAC in vitro and in vivo of 
vincristine-resistant oral epidermoid carcinoma cells (KB/V cells) with P-gp overexpression. 
It found that the anti-tumour activity of DHPAC is closely related to its inhibition of tubulin 
polymerization and PTEN/Akt/NF-κB signalling.  
2. Materials and Methods  
2.1 Compounds 
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  Compound DHPAC and colchicine (Figure 1) were synthesized at Institute of Medicinal 
Chemistry, School of Pharmaceutical Sciences, Shandong University. Compound DHPAC, 
white solid, mp 186−188°C; 1H NMR (600 MHz, DMSO-d6) δ 1.32 (t, J = 7.2 Hz, 3H), 1.37 
(t, J = 7.2 Hz, 3H), 3.39 (s, 2H), 3.94 (s, 3H), 3.98 (q, J = 7.2 Hz, 2H), 4.10 (q, J = 7.2 Hz, 
2H), 4.53 (s, 2H), 6.30 (dd, J = 8.4,1.8 Hz, 1H), 6.83 (dd, J = 8.4,1.8 Hz, 1H), 6.98(t, J = 1.8 
Hz, 1H), 7.06 (t, J = 7.8 Hz, 1H), 7.27 (s, 1H), 7.37 (s, 1H), 7.39 (s, 1H), 7.50 (s, 1H), 8.38 (s, 
1H); 13C NMR (100 MHz, DMSOd6) δ 170.9, 159.7, 148.6, 147.9, 147.2, 145.4, 144.9, 143.4, 
129.8, 124.9, 112.8, 112.7, 108.3, 107.6, 104.4, 101.9, 69.8, 64.7, 63.1, 37.5, 29.5, 15.3; MS 
(ESI) m/z 423.4 (M + H)+, 445.5 (M + Na)+; Anal. calcd for C23H26N4O4 (Liu et al., 2016). 
DHPAC and colchicine were both dissolved in dimethyl sulfoxide (DMSO) and stored at 
-20°C.  
2.2 Materials 
  Paclitaxel was obtained from Sangon Biotech (Shanghai, China) with purity > 98%. 
Vincristine sulfate was purchased from Lingnan Pharmaceutical LTD (Guangzhou, China). 
Doxorubicin freeze drying agent was purchased from Pfizer (Actavis, Italy). Fluorouracil 
Injection was purchased from Shanghai XudongHaipu Pharmaceutical CO. LDT (Shanghai, 
China). Verapamil Hydrochloride Injection was obtained from Shanghai Harvest 
Pharmaceuticals (Shanghai, China). Trypsin solution, crystal violet dye,3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), propidium iodide (PI), 
bovine serum albumin (BSA), hoechst 33342 and phenylmethanesulfonyl fluoride (PMSF) 
were purchased from Solarbio technology (Beijing, China). Radio immunoprecipitation assay 
(RIPA) lysis buffer, JC-1 fluorescence probekit, rhodamine123 (Rh123) were purchased from 
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Beyotime biotechnology (Shanghai, China). Annexin V-FITC apoptosis detection Kit was 
purchased from 4A Biotech. (Beijing, China). Z-VAD-FMK was purchased from Selleck 
(Shanghai,China). Monoclonal antibodies against Bax, Bcl-2, caspase 9, caspase 3, PARP, 
Phospho-cdc2 (p-cdc2, Tyr15), cdc2, cyclin B1, cdc25B, Phospho-Akt (p-Akt, Ser473), PI3K, 
Phospho-PTEN (p-PTEN, Ser380/Thr382/Thr383), NF-κB, P-glycoprotein (P-gp) and 
α-tubulin were purchased from Cell Signaling Technology (CST, Boston, MA, USA). 
Monoclonal antibodies against PTEN, cytochrome c, caspase 8, RSK2 and Akt were 
purchased from proteintech (Wuhan, China), RPMI-1640 medium, fetal bovine serum was 
purchased from Gibco (Gaithersburg, MD, USA).  
2.3 Cell Culture 
Human oral epidermoid carcinoma cell line KB, human breast cancer cell line MCF-7, 
Adriamycin (ADR) selected MDR subline MCF-7/ADR and human hepatocellular carcinoma 
cell line BEL7402, 5-fluorouracil (5-FU) selected MDR subline BEL7402/5-FU were 
purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Vincristine 
(VCR) selected MDR subline KB/V was obtained from Sun Yat-Sen University of Medical 
Sciences (Guangzhou, China). All of these cells were cultured in RPMI-1640 medium 
supplemented with 10% FBS at 37°C in a humidified atmosphere of 5% CO2 and 95% air. In 
order to maintain the MDR phenotype, KB/V cells were cultured in medium with 40 nM 
vincristine, K562/A02 cell with 1μM doxorubicin and BEL7402/5-FU with 2 mM 
5-fluorouracil. Drugs were removed one week before the experiment (Xu et al., 2012; Yang et 
at., 2012; Yue et al., 2013). 
2.4 Cell proliferation assay 
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  The inhibitory effects of different compounds on the proliferation of various human cancer 
cell lines and multidrug resistant cell lines were measured by the MTT assay. Briefly, cells 
(800~2000 per well) were seeded into 96-well plates and grown for 24 h before treatment 
with various concentrations of compounds for a further 24 h or 48h. 20 μL of MTT solution 
(5mg /mL) was added to each well for 4h at 37 °C. Then the formazan crystals were dissolved 
in 200 μL of DMSO solution before the absorbance was measured using the Thermo 
Multiskan GO microplate reader (Thermo-1510, CA, USA) at a wavelength of 570 nm (Zhao 
et al., 2012). 
2.5 Colony formation assay 
KB/V cells (300 per well) seeded into 6-well plates were treated with different 
concentrations (20, 30, 40 nM) of DHPAC for 24h, and then were cultured in drug-free 
medium for 10 days. Colonies were fixed in ice-cold methanol/glacial acetic acid (3:1, v/v) 
for 10 minutes and stained with 0.8% crystal violet, and then were imaged and counted under 
the microscope (CKX31SF, Olympus, Japan). 
2.6 Rhodamine 123 (Rh123) accumulation assay 
KB/V cells (3.5×105 per well) seeded into 24-well plates were treated with different 
concentrations (20, 40, 80 nM) of DHPAC or 10.0 μM verapamil (Ver) (positive control) for 
3h. KB cells were treated with vehicle as negative control. Then 5μM Rh123 was added to 
each well in dark at 37°C for 1h. After washing cells with ice-cold phosphate buffered saline 
(PBS) repeatedly, the images were taken by fluorescence microscopy (200×, TE2000-S; 
Nikon, Tokyo, Japan). 
2.7 Immunofluorescence staining 
 8 
  KB/V cells were seeded into 24-well plate (with coverslips inserted) at density of 4×104 
cells per well. After overnight culture at 37℃, cells were exposed to DHPAC (20 or 80nM) or 
colchicine (80nM) for 24 h. The cells were fixed with ice-cold methanol/glacial acetic acid 
(3:1) for 10 min and blocked with 3% bovine serum albumin (BSA) in PBS for 20 min at 
room temperature. Then cells were incubated with a mouse anti-α-tubulin antibody (1:200) 
overnight at 4°C and followed by reaction with FITC-conjugated secondary antibody (1:500) 
for 2h at 37℃. Finally, cells were stained with hoechst 33342 to mark the nuclear, and 
fluorescence images were taken with fluorescence microscope (200×, TE2000-S; Nikon, 
Tokyo, Japan). 
2.8 Nuclear morphology analysis 
KB/V cells were seeded in 24-well plates at a density of 4×104 cells per well. After 
introduction of various concentrations of DHPAC for 24 h, the cells were fixed in 4% 
paraformaldehyde in PBS for 30min, and then stained with hoechst 33324 (10μg/ml) in dark 
at room temperature for 15 min. After three washes with PBS, the cells were visualized with 
fluorescence microscopy (200×, TE2000-S; Nikon, Tokyo, Japan). 
2.9 Annexin V/PI staining assay 
  KB/V cells seeded in 6-well plate (2×105 per well) were treated with DHPAC (20nM, 
40nM, 80nM) or colchicine (80nM) for 48h. The cells were harvested, washed with cold PBS 
and the cell surface phosphatidylserine in apoptotic cells was determined using 
AnnexinV/FITC and PI apoptosis detectionkit (ydjmbio, China) according to manufacturer’s 
instructions and analyzed by a FACScan flowcytometry (Becton Dickinson, Franklin Lakes, 
New Jersey, USA) using emission filters of 525 and 575 nm respectively (Lu et al., 2015; 
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Wang et al., 2016). 
2.10 Cell cycle analysis 
KB/V cells (5×105 cells per well) were plated in 60mm plates and exposed to 20nM, 40nM, 
80nM DHPAC or 80nM colchicine for 24 h. The cells were harvested, washed twice with cold 
PBS and fixed with pre-cooled 70% ethanol at -20°C overnight. After washing with PBS 
twice, the cells were incubated with RNase A (100 μg/mL) for 30 min at 37 °C before 
addition of propidium iodide (PI) for DNA staining in the dark at 4°C for 15 min. Cell cycle 
distribution was analyzed and quantified using a FACSort flow cytometry (Beckman coulter, 
USA). 
2.11 Western Blotting analysis 
  After treatment with DHPAC, cells were harvested and lysed with lysis buffer containing 
proteinase inhibitors (PMSF) at 99:1, v/v. With centrifuging at 15000g for 15 min, the total 
protein concentrations were determined using BCA protein assay kit (Thermo Scientific, 
USA). Loading buffer (Beyotime, China) was added into each samples and the samples were 
heated at 100°C for 5 min. Cell lysates were subjected to 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) followed by protein transfer to a PVDF membranes (Millipore, USA) 
and probed with primary antibodies (1:1000) against P-gp, cyclin B1, p-cdc2, cdc2, cdc25B, 
cdc25C, RSK2, PARP, caspase 9, caspase 3, caspase 8, Bcl-2, Bax, cytochrome c, PTEN, 
p-PTEN, p-Akt, Akt, PI3K, NF-κB and β-actin (1:1000 in primary antibody diluent) at 4°C 
overnight. Immunoblots were developed using horseradish peroxidase (HRP)-conjugated 
secondary antibodies (1:10000), and visualized by the enchanced chemiluminescent (ECL) 
system (Millipore, Billerica, MD, USA) and quantified by densitometry using a ChemiDoc 
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XRS (Bio-Rad, Hercules, California, USA). There relative intensity of each band was 
normalized to β-actin.  
2.12 Measurement of mitochondrial membrane potential  
Mitochondrial membrane potential (MMP) was evaluated by using fluorescent 
carbocyanine dye JC-1 which can selectively enter mitochondria and reversibly change color 
from red to green as the MMP decreased (Otera and Mihara, 2012). KB/V cells (1.5×105 cells 
per well) seeded in 6-well plates were exposed to 20nM, 40nM, 80nM DHPAC or 80nM 
colchicine for 48h. Cells were harvested and incubated with JC-1 for 20 min at 37 °C. 
Fluorescence intensity was measured immediately by FACSort flow cytometer (Beckman 
coulter, USA). 
2.13 Assessment of DHPAC antitumor activity in vivo 
Five-week-old female Balb/C nude mice were purchased from the Animal Centre of China 
Academy of Medical Sciences (Beijing, China) and acclimated and caged in 5 groups. 
Animals were housed under pathogen-free conditions. The research protocol was in 
accordance with the Institutional Guidelines of Animal Care and Use Committee of Shandong 
University. After one week of feeding, KB/V xenografts were established by inoculating 
8.0×106 KB/V cells subcutaneously into armpit of nude mice under sterile conditions. When 
the xenografts volume reached approximately 500 mm3, the animals were sacrificed and the 
tumors were extracted and cut into 1 mm3 fragments (about 20mg/fragment). One fragment 
was transplanted subcutaneously into the right flank by trocar in each nude mouse. When the 
solid tumor reached a volume of 100 mm3 to 200 mm3, the mice were divided into six groups 
(n=6) at random: blank control group (normal saline), vehicle control group (Castor Oil: 
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ethanol: dextrose 5% in water (D5W) = 1:1:4), DHPAC (15 mg/kg, 30 mg/kg) group, and 
paclitaxel (10mg/kg) group. DHPAC and vehicle were given every day by intraperitoneal 
injection for 20 days. Paclitaxel was given 7 days then suspended for 3 days, followed by 10 
days injection. The tumor and body weight of the mice were measured every 3 days. Tumor 
volume was calculated as W2×L/2. At the end of the experiment, the mice were sacrificed and 
the xenografts were removed and weighed. Effect of DHPAC on tumor growth was expressed 
as a percentage to that in the vehicle control group. 
2.14 Statistical analysis 
  All quantitative dates are expressed as mean ± SD. Statistical comparisons were performed 
by one-way analysis of variance. A P-value < 0.05 was considered statistically significant. 
Statistical analysis was performed using the SPSS/Win 13.0 software. 
 
3. Results 
3.1 DHPAC inhibits KB/V cells proliferation in vitro 
The phenotype of MDR in KB/V, Bel7402/5-FU, and MCF-7/ADR cells was determined 
by MTT assay. In comparison with their parental cells, MDR cells showed significant 
resistance to cytotoxic killing by VCR, 5-FU or ADR, respectively. As shown in Table 1, a > 
164-fold increase of resistance for 5-FU in Bel7402/5-FU cells, a > 115-fold increase of 
resistance for VCR and a > 29 increase for paclitaxel in KB/V cells were observed. The 
anti-proliferative activity of DHPAC or colchicine against the above MDR cancer cells and 
their parental cells were also determined by MTT assay (Table 2). All the three MDR cell 
lines exhibited resistance to colchicine. DHPAC showed to induce similar inhibitory effects 
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on the growth of MCF-7/ADR and Bel7402/5-FU cells as colchicine, but better inhibition 
than colchicine, vincristine or paclitaxel on the growth of KB/V cells (IC50 value was 64.4 nM 
for DHPAC, 458.0 nM for colchicine, 427.3 nM for vincristine, 574.9 nM for paclitaxel). 
These indicated an excellent anti-proliferative activity of DHPAC in KB/V cells. Moreover, 
DHPAC at concentrations from 6.25 nM to 100 nM inhibited the proliferation of KB/V and 
KB cells in a dose-dependent manner, while the IC50 values of colchicine in KB/V cells were 
much bigger than that in KB cells at different time points (IC50 value were 458.0, 138.2, 120.0 
nM in KB/V and 33.1, 14.6, 7.6 nM in KB cells). (Table 3 and Figure 2B). 
The cytotoxicity of DHPAC in KB/V cells was further evaluated by colony formation assay. 
As shown in Figure 2A, the presence of DHPAC at the concentrations 20 nM to 40 nM 
showed 30.3%, 67.7%, 93.1%, respectively, inhibition of colony formation of KB/V cells. 
Colchicine at 40 nM showed to cause 17.2% inhibition of colony formation of these cells. At 
equal dosage (e.g.40nM) DHPAC also showed stronger inhibition of colony formation than 
colchicine (p < 0.01). 
3.2 DHPAC inhibits tumor growth in mice implanted with KB/V cells  
   Administration of DHPAC resulted in significant inhibition on growth of KB/V tumor 
xenografts in nude mice (Figure 2C, Table 4). Treatment of nude mice with DHPAC at 
30mg/kg by intraperitoneal injection resulted in 75.8 % reduction of tumor growth (p < 0.01) 
after 20 days in comparison to the vehicle control group (Castor Oil: ethanol: dextrose 5% in 
water (D5W) = 1:1:4). Administration of paclitaxel at 10mg/kg caused 24.1% growth 
inhibition. There were no significant difference of tumour size and body weight between the 
vehicle control and blank control groups, indicating no inhibitory and cytoxic activity of the 
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vehicle. The animals demonstrated general tolerance with DHPAC treatment and weak loss of 
the body weight was observed only in high dose group. On the other hand, the animals 
administrated with paclitaxel showed dramatic reduction of body weight from day 6 (Figure. 
2D). 
3.3 DHPAC is not a substrate of P-gp efflux pump and has no effect on the activity and 
expression of P-gp in KB/V cells 
Rhodamine-123 (Rh123) is a low toxic fluorescent probe and is often used to detect the 
activity of P-gp efflux pump. As illustrated in Figure 3A, the fluorescence intensity (FI) of 
Rh123 in KB/V cells was much lower than that in KB cells, suggesting higher P-gp activity in 
KB/V cells. After treatment with 10 μM of verapamil (Ver, inhibitor of P-gp in MDR), the FI 
in KB/V cells increased significantly in comparison to vehicle-treated KB/V cells. No 
significant difference of the FI was seen in KB/V cells treated with either different 
concentrations of DHPAC or colchicine in comparison with vehicle-treated KB/V cells. P-gp 
expression was much higher in KB/V cells than in KB cells when analyzed by Western blot. 
The presence of DHPAC at 20, 40, 80 nM or colchicine at 80 nM had no obvious effects on 
P-gp expression in KB/V cells (Figure 3B). 
3.4 DHPAC inhibits tubulin polymerization and induces G2/M phase arrest in KB/V cells. 
The effects of DHPAC on microtubule organization were investigated with 
immunofluorescence staining of α-tubulin. As shown in Figure 4, the microtubule networks 
exhibited a normal arrangement with slim and fibrous microtubules wrapped around the cell 
nucleus in untreated or vehicle-treated cells. However, after the cells treated with DHPAC at 
20nM or 80nM for 24h, the microtubule bundles became shorter and disoriented with diffused 
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fluorescent staining throughout the cytoplasm. Nuclear fragmentation and microtubule 
condensation were also clearly observed in DHPAC-treated cells. At equal dose of 80 nM, 
DHPAC again showed better effects than colchicine on inhibition of tubulin polymerization. 
It is known that microtubule-targeting agents often regulate the cell cycle by blocking 
mitosis. Treatment of the cells with DHPAC induced an accumulation of cells in the G2/M 
phase dose-dependently, whereas the control cells were mainly in the G1 phase. As shown in 
Figure 5, DHPAC, approximately 90.3% of KB/V cells were arrested at G2/M phase after 
treatment with 80nM DHPAC for 24h. At similar concentration, colchicine induced 25.5% 
rest of the cells in the G2/M phase. When association between DHPAC-induced the arrest of 
G2/M phase and alterations in proteins that regulated cell division were analysed (Figure 5B), 
DHPAC induced down-regulation of cdc2, p-cdc2 and cdc25B, cdc25C, RSK2, up-regulation 
of cyclinB1 in a concentration-dependent manner. At 80nM, DHPAC induced stronger 
down-regulation of cdc2, p-cdc2, cdc25C, RSK2 and cdc25B than colchicine (P < 0.05).  
3.5 DHPAC induces apoptosis in KB/V cells through regulating the expressions of 
apoptotic-related proteins and decreasing mitochondrial transmembrane potential 
The effects of DHPAC on KB/V cells apoptosis were firstly examined through hoechst 
33342 nuclear staining assay. As shown in Figure 6A, treatment of KB/V cells with DHPAC 
at 40 or 80 nM for 24h increased the number of cells with condensed chromatin (white arrows) 
and fragmented nuclei (yellow arrows), characteristics of apoptosis, in comparison to vehicle 
(DMSO)-treated and 80 nM colchicine-treated groups. Apoptosis induction of the cells by 
DHPAC was confirmed by flow cytometric analysis using PI and Annexin-V-FITC double 
staining. The cells can be differentiated to normal live cells (Annexin V-/PI- cells), early 
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apoptotic cells (Annexin V+/PI- cells), necrosis/late apoptotic cells (Annexin V+/PI+ cells) in 
this analysis. In Figure 6B, at concentrations of 20, 40 and 80 nM for 48h, DHPAC induced 
8.5%, 20.9%, and 30.9%, respectively, while colchicine induced only 5.8% apoptosis at 80 
nM.  
 KB/V cells were pretreated with the pan caspase inhibitor Z-VAD (30 μM) for 1 h before 
exposure to DHPAC. The apoptosis of KB/V cells was determined by Annexin V/PI staining 
assay using FACScan flow cytometry. Results showed that in the presence of 30 μM z-VAD, 
the apoptosis rate induced by 80 nM DHPAC had significantly decreased from 23.6% to 
12.3%, and the increased cleaved PARP expression induced by DHPAC was also inhibited (P 
<0.05) in Figure 7. 
Mitochondria-mediated apoptosis is controlled by the Bcl-2 family of proteins, with the 
activation of caspase 9, the decrease in mitochondrial transmembrane potential (MMP) and 
the cytochrome c releasing. Fluorescent carbocyanine dye JC-1 was used to assess the effect 
of DHPAC on MMP. As shown in Figure 8A, the red fluorescence of JC-1 (high Δψm) was 
gradually decreased and the green fluorescence (low Δψm) was correspondingly increased 
after the treatment of DHPAC or colchicine. At 20, 40, 80 nM of DHPAC, the high Δψm was 
decreased by 16.1%, 21.6%, and 46.2%, respectively, while colchicine decreased Δψm by 
14.9%. The pro-apoptotic proteins Bax were seen to be increased and the anti-apoptotic 
proteins Bcl-2 were decreased after DHPAC treatment. DHPAC at 80nM decreased the ratio 
of Bcl-2/Bax by 59.2% compared with vehicle control. Meanwhile, the expression of cleaved 
PARP, cleaved caspase 9 and cytochrome c was increased 10.3, 2.1 and 2.02 times, 
respectively, in response to 80 nM DHPAC treatment (Figure 8B). However, DHPAC had no 
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significant effect on the expression of caspase 8. 
3.6 DHPAC disrupted PTEN/Akt/NF-κB signal pathway in vitro and in vivo 
  PI3K/Akt signal pathway plays a major role in cell survival and is activated in many tumor 
cells. As shown in Figure 9A, DHPAC treatment of the cells strongly reduced the levels of 
NF-κB, p-Akt, Akt and p-PTEN in a dose-dependent manner in KB/V cells. It also induced a 
weak decrease on the expression of PI3K, while had no significant effect on PTEN expression.  
Moreover, cytoplasmic as well as nuclear localization of NF-κB, was markedly decreased by 
the treatment of DHPAC (Figure 9B). In Figure 9C, after treatment of the cells with bpV 
(phen), a PTEN inhibitor, DHPAC induced remarkably higher expression of p-Akt and NF-κB 
in comparison with DHPAC treatment alone. What’s more, the expression of p-Akt and 
NF-κB in co-treatment group of Bpv and DHPAC was lower obviously than Bpv treatment 
alone. Meanwhile, DHPAC treatment in mouse xenografts of KB/V cells also showed to 
dramatically decrease the expression of p-PTEN, p-Akt, NF-κB (Figure 9D).  
 
4. Discussion 
Computer-aided drug design (CADD) has been increasingly used in drug development, 
according to provide some useful directions in the optimal design and discovery of anti-cancer 
drugs. DHPAC is a novel agent which targeted on colchicine binding site at the interface 
between the α- and β-subunit of tubulin heterodimers in zone 1 and was initially obtained by 
CADD (Liu et al., 2016). In comparison to the other tubulin binding region (taxane or vinca 
alkaloid binding sites), targeting the colchicine binding site may provide a better opportunity 
for structural optimization to overcome drug resistance while complied with Lipinski’s Rule 
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of Five (Hwang et al., 2015; Lipinski et al., 2001). In the present study, the anti-proliferative 
activity of DHPAC and colchicine (a positive control in vitro assay) against several human 
MDR cancer cell lines (KB/V cells, MCF-7/A cells, BEL7402/5-FU cells) and their parental 
cell lines were compared. Results showed that DHPAC has higher anti-tumor selectivity in 
KB/V cells than colchicine in vitro and in KB/VCR xenografts in nude mice. In the process of 
mitosis, microtubules undergo rapid polymerization and depolymerization to ensure the 
movement of chromosomes, essential for cell replication and proliferation. Disruption of 
microtubule dynamics or reduction of microtubule polymer mass leads to G2/M arrest (Chang 
et al., 2015). Cdc2 (also called cyclin-dependent kinase 1 (CDK1) and cyclinB1 are the key 
regulatory proteins of G2/M. Before mitosis, cdc2/cyclinB1 complex accumulates in 
cytoplasm as an inactive form as a result of cdc2 phosphorylation at Thr14 and Tyr15 (Sur 
and Agrawal, 2016). Removal of the cdc2 phosphate groups at Thr14/Tyr15 by cdc25 
activates the cdc2/cyclinB1 complex and promotes G2 to M transition (Sur and Agrawal, 
2016; Bulavin et al., 2003). The activated CDK1/cyclinB1 complex has a positive feedback 
loop to further activate cdc25. RSK, a 90-kDa ribosomal S6 kinase, plays an important role in 
the phosphorylation and activation of cdc25 in the process of G2/M transition. RSK2 is the 
major isoform of RSK which reveals the capacity to activate cdc25C (Wu et al., 2014). 
Mitosis is blocked in the absence of CDC25 or cdc2/cyclinB1 complex (Deibler and 
Kirschner, 2010; Loffler et al., 2006). In our study, DHPAC at 80 nM showed to induce 
disintegration of microtubule skeleton and extensive loss of microtubule mass, characteristics 
of microtubule depolymerization, an effect that is accompanied by G2/M arrest of the cells. 
DHPAC also showed better ability to induce microtubule depolymerization and G2/M arrest 
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than colchicine at the same concentration. DHPAC treatment reduces the expression of cdc2, 
p-cdc2 (Tyr15), cdc25C, RSK2 and cdc25B, depresses the formation and activation of 
cdc2/cyclinB1 complex, leading to G2/M arrest.  
  Many anti-tumor drugs induce G2/M arrest and cell apoptosis (Schwartz and Shah, 2005). 
Apoptosis is a programmed cell death with two signaling pathways, the extrinsic pathway (the 
death receptor pathway) and the intrinsic pathway (mitochondrial pathway). Mitochondrial 
mediated pathway is mainly regulated by Bcl-2 family. In response to apoptotic signals, 
reduction of the ratio of Bcl-2/Bax decrease the mitochondrial membrane potential (MMP) 
and causes the release of cytochrome c. The released cytochrome c in cytoplasm activates 
caspase 9, caspase 3, followed by cleavage of specific substrate proteins, such as PARP (Zhao 
et al., 2016; Sun et al., 2010). In the present study, DHPAC treatment was observed to induce 
apoptosis by decreasing the level of MMP and Bcl-2/Bax complex ratio. This resulted in the 
release of cytochrome c and activation of caspase 9 and PARP cleavage. Combined use of 
caspase inhibitor V-ZAD with DHPAC leaded to the reduction of apoptosis rate, indicating 
that DHPAC induced apoptosis was associated with caspase pathway ulteriorly. Moreover, we 
found that DHPAC had no significant effect on the expression of caspase 8, suggesting that 
DHPAC induced apoptosis of KB/V cells by intrinsic apoptosis pathway preferentially. 
As a regulator of cell survival, PI3K/Akt/NF-κB signaling is constitutively activated in oral 
carcinogenesis (Watanabe et al., 2009; Amornphimoltham et al., 2004). Dysregulation of 
PTEN/PI3K/Akt signaling contributes to the development of chemotherapeutic resistance of 
tumor cells (Hafsi et al., 2012). Phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) is a well-known tumor suppressor protein that regulates many cellular processes, 
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including cell death and proliferation, through the PI3K/Akt/NF-κB signalling (Squarize et al., 
2013; Molinolo et al., 2009; Xie et al., 2016). PTEN is composed of five functional domains: 
a phosphatase domain, a C2 domain, a phosphatidylinositol-4, 5-bisphosphate (PIP2)-binding 
domain (PBD), a C-terminal tail containing PEST and a PDZ interaction motif for 
protein-protein interactions (Chalhoub and Baker, 2009). It has been suggested that cytosolic 
PTEN exists as an inactive conformation with phosphorylation of its C-terminal tail (Vazquez 
and Devreotes, 2006). Dephosphorylation of p-PTEN resulted in sensitization of the PTEN 
protein (Fragoso and Barata, 2014; Kohnoh et al., 2016). As a lipid phosphatase to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), PTEN mediates transformation of PIP3 to 
PIP2, while PI3K has the inverse function to transform PIP2 to PIP3 (Wang et al., 2016). In 
this study, treatment of KB/V cells with DHPAC strongly inhibited phosphorylation of PTEN 
and Akt, and the expression of Akt and NF-κB (in cytoplasm and nucleus) both in vitro and in 
vivo. However, DHPAC had no effect on PTEN expression. To further explore the effect of 
DHPAC on PTEN/Akt/NF-κB signalling pathway, Bpv (phen), a potent protein 
phosphotyrosine phosphatase (PTP) inhibitor (Spinelli et al., 2015; Schmid et al., 2004) that 
inhibits the dephosphorylation of PIP3 by PTEN, was used. Higher expression of p-Akt and 
NF-κB in co-treatment of DHPAC and Bpv than DHPAC alone reveals that the effect of 
DHPAC on PTEN/PI3K/Akt/NF-κB signaling was reversed after phosphatase activity of 
PTEN being suppressed. These indicated that DHPAC might inhibit PTEN/PI3K/Akt/NF-κB 
signaling by increasing the activation of PTEN, in association with promoting the 
transformation of p-PTEN to PTEN. Moreover, the expression of p-Akt and NF-κB in 
co-treatment of Bpv and DHPAC was lower obviously than Bpv treatment alone. This further 
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verified that DHPAC inhibited the phosphorylation of PTEN as well as downregulation of Akt 
expression, resulting in a reduction of NF-κB in the nucleus which suppressed the activation 
of its target gene products e.g. Bcl-2, Bcl-xl and survivin (Lakshma Nayak et al., 2016). These 
suggest that the inhibitory effects of DHPAC on proliferation in KB/V cells were closely 
associated with suppression of PTEN/Akt/NF-κB signaling. 
In conclusion, DHPAC, a novel compound that binds to the same colchicine binding site of 
microtubules, possesses highly potent anti-cancer activities in MDR tumors in vitro and in 
vivo. It induces G2/M cell arrest and apoptosis in KB/V cells in vitro and inhibits growth of 
KB/V xenografts in nude mice without any significant cytoxicity. In addition to its binding to 
microtubule, DHPAC may effect on PTEN in KB/V cells and inhibit PTEN/Akt/NF-κB 
signaling. Therefore, DHPAC may be a promising agent for the treatment of 
vincristin-resistant human oral epidermoid carcinoma. 
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Figure legends 
 
Figure 1. The chemical structure of colchicine and DHPAC 
 
Figure 2. DHPAC inhibits the proliferation of KB/V cells. A. Representative colony 
formation images of KB/V cells after treatment with DHPAC for 24h, then in DHPAC-free 
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medium for 12 days. The colonies which were greater than 50 cells were counted under the 
dissecting microscope and inhibition was denoted as percentage to the control group. B. Cell 
proliferation was asessed by MTT assay after incubation with DHPAC or colchicine for 
different time (24h, 48h, 72h). KB/V xenografts were established by inoculating KB/V cells 
subcutaneously. DHPAC was administrated by intraperitoneal injection every day for 20 days. 
At the end of experiment, the mice were sacrificed and the tumors were weighed. C, tumor 
images for each group. The body weight (D) and tumor volume (E) were measured every 3 
days. Data are presented as mean ± SD. *p < 0.05 , **p < 0.01 vs. vehicle group; ##p < 0.01 vs. 
40 nM DHPAC group. 
 
Figure 3. DHPAC has no effect on expression and activity of P-gp in KB/V cells. A. Effect of 
DHPAC on P-gp activity was evaluated by detecting the intracellular accumulation of Rh123. 
KB/V cells were treated with vehicle medium (0.4% DMSO medium), verapamil, colchicine 
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and different concentrations of DHPAC, and KB cells were treated with vehicle medium, then 
stained with Rhodamine 123, and photographed under fluorescence microscopy (20× 
magnification; scale bar = 20μm). B. The expression of P-gp in KB/V cells was detected and 
quantized using Western blotting. Triplicate experiments were performed. **P < 0.01 vs. KB/V 
vehicle group. 
 
Figure 4. DHPAC inhibits cellular microtubule network in KB/V cells . Cells were treated 
with blank (10% FBS medium), control (0.4% DMSO), DHPAC (20 nM, 80 nM) or 
colchicine (80 nM) for 24h before images of the cells were taken by fluorescence microscopy 
(20× magnification; scale bar = 20μm). Microtubules were labeled by anti-α-tubulin antibody 
with FITC-conjugated secondary antibody (green), and nucleus was labeled with hoechst 
33342 (blue). 
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Figure 5. DHPAC arrests KB/V cells in G2/M phase by regulating the expression of G2/M 
related proteins. A. Cells were treated with different concentrations of DHPAC or colchicine 
(80nM) for 24 h and followed by cell cycle analysis by flow cytometry. B. The expression of 
G2/M regulatory proteins was detected by Western blotting (mean ± SD, n=3). *P < 0.05, **P 
< 0.01 vs. control group. #P < 0.05, ##P < 0.01 vs. colchicine group.  
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Figure 6. DHPAC induces apoptosis in KB/V cells. A. Cells were treated with different 
concentrations of DHPAC or colchicine (80 nM) for 24 h, before stained with hoechst 33342. 
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White arrows indicated characteristics of chromatin condensation, yellow arrows indicated 
apoptotic bodies. B. Apoptotic cells was detected by Annexin-FITC and PI double-staining 
and analyzed by flow cytometry. live cells (Q1-LL), early apoptotic cells (Q1-LR), late 
apoptotic cells (Q1-UR) were indicated (mean ± SD, n=3). *P < 0.05, **P < 0.01 vs. vehicle 
group; ##P < 0.01 vs. colchicine group. 
 
Figure 7. DHPAC induced-apoptosis was inhibited by z-VAD. A. KB/V cells were pretreated 
with Z-VAD-FMK (30 μM) for 1 h before exposure to 80nM DHPAC for 48h. Apoptotic 
cells were detected by Annexin-FITC and PI double-staining and analyzed by flow cytometry. 
B. Apoptotic-related protein PARP was detected by Western blotting (mean ± SD, n=3). *P < 
0.05 vs. 80 nM DHPAC group. 
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Figure 8. DHPAC induces apoptosis of KB/V cells. A. after exposure to different 
concentrations of DHPAC or colchicine (80nM) for 48 h, KB/V cells were stained by JC-1 
and analyzed by flow cytometry for mitochondrial depolarization. The red and green gates 
represent high and low mitochondrial potential, respectively. B. Apoptosis-related proteins 
were detected by Western blotting (mean ± SD, n=3). *P < 0.05 and **P < 0.01 vs. control. #P 
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< 0.05 vs. colchicine group. 
 
Figure 9. DHPAC inhibit KB/V cell growth by suppressing PTEN-Akt-NF-κB signaling. A. 
KB/V cells were incubated with DHPAC (20nM, 40nM, 80nM) and colchicine 80 nM for 24h 
followed by analysis of the expression of PI3K, Akt, PTEN, p-Akt, p-PTEN 
(Ser380/Thr382/Thr383), and NF-κB in KB/V cells by Western blotting. B. NF-κB was 
detected both in cytoplasm (NF-κB C) and nucleus (NF-κB N) after treatment with DHPAC 
or colchicine. C. Representative blots of PI3K, PTEN, p-Akt and NF-κB in KB/V cells treated 
with DHPAC for 24h with or without PTEN inhibitor bpV (phen) are shown. D. 
Representative blots of PTEN/Akt/NF-κB signaling proteins in KB/V cells xenografts are 
shown. E, F, G: Quantification and statistical analysis of the protein bands in A, B and C, 
respectively. Data are expressed as mean ± SD (n=3). *P < 0.05, **P < 0.01 vs. vehicle group. 
+P < 0.05, ++P < 0.01 vs. 40 nm DHPAC co-treated with Bpv group.  
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Table 1. Resistance determination of different drug resistant cell lines at 48h (mean ± SD, 
n=3) 
Drugs IC50 RF 
 KB KB/V  
vincristine  3.7 ± 0.1nM 427.3 ± 28.3nM 115 
paclitaxel 20.0 ± 3.1nM 574.9 ± 20.9nM 29 
 BEL7402 Bel7402/5-FU  
5-fluorouracil   0.2 ± 0.06mM 31.2 ± 9.2mM 164 
 MCF-7 MCF-7/A  
doxorubicin  2.6 ± 0.8μM 22.7 ± 8.1μM 8 
RF (resistant fold) = IC50 against resistant cells/ IC50 against sensitive cells. 
 
Table 2. IC50 values of DHPAC and colchicine against various human cancer cell lines for 24h 
(mean ± SD, n=3)  
 
Cell lines  
IC50 (nM) 
DHPAC colchicine 
Bel7402    88.3 ± 11.9  91.7 ± 27.0 
Bel7402/5-FU   226.3 ± 34.4  296.7 ± 64.9 
KB 47.4 ± 1.6 34.2 ± 1.6 
KB/V 64.4 ± 2.8 458.0 ± 34.1 
MCF-7 60.0 ± 4.9  77.0 ± 14.6 
MCF-7/A 281.3 ± 30.8 334.0 ± 29.5 
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Table 3. IC50 values of DHPAC and colchicine against KB/V and KB cells at different times 
points (mean ± SD, n=3) 
 
Table 4. Inhibitory effects of DHPAC on growth of KB/V xenografts in athymic mice (mean ± 
SD) 
Groups Mice (n) 
initial/en
d 
Body weight (g) 
initial/end 
Tumor weight 
(g) 
Inhibition 
rate (%) 
Blank 6/6 20.6 ± 0.4 / 23.8 ± 0.7   2.2 ± 1.0 — 
Vehicle 6/6 20.3 ± 0.4 / 23.8 ± 1.1   2.1 ± 0.8 — 
DHPAC 15 mg/kg 6/6 20.8 ± 1.0 / 22.9 ± 0.7   1.5 ± 0.3* 25.1 
DHPAC 30 mg/kg 6/6 20.1 ± 0.8 / 21.4 ± 0.4 0.5 ± 0.2** 75.8 
Paclitaxel 10 mg/kg 6/6 20.7 ± 0.4 / 19.8 ± 1.8*   1.7 ± 0.5 24.1 
 *P < 0.05, **P < 0.01 vs. vehicle group. 
Note: The data of body weight (end) for statistical analysis have been deducted tumor weight.  
 
 
 
 
Drugs  
IC50 (nM) 
24h ( KB/V / KB)     48h ( KB/V / KB)    72h ( KB/V / KB) 
DHPAC 
  
 64.4 ± 2.8 / 46.3 ± 1.4  29.3 ± 2.5 / 28.7 ± 3.7  23.8 ± 1.8 / 23.5 ± 3.2 
colchicine 458.0 ± 34.1 / 33.1 ± 1.6 138.2 ± 1.2 / 14.6 ± 0.7 120.0 ± 9.1 / 7.6 ± 0.7 
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